MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318676 | Name: Ropinirole HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ropinirole, also known as AS-041164, SKF 101468, is a potent and selective PI3Kgamma inhibitor. Ropinirole is prescribed for mainly Parkinson's disease, RLS and extrapyramidal symptoms. It can also reduce the side effects caused by selective serotonin reuptake inhibitors, including Parkinsonism syndrome as well as sexual dysfunction and erectile dysfunction caused by either SSRIs or antipsychotics.

Chemical Structure

Ropinirole HCl
Ropinirole HCl
CAS#91374-20-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 318676

Name: Ropinirole HCl

CAS#: 91374-20-8 (HCl)

Chemical Formula: C16H25ClN2O

Exact Mass:

Molecular Weight: 296.84

Elemental Analysis: C, 64.74; H, 8.49; Cl, 11.94; N, 9.44; O, 5.39

Price and Availability

Size Price Availability Quantity
25mg USD 250.00 2 Weeks
50mg USD 450.00 2 Weeks
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 2,150.00 2 Weeks
1g USD 3,250.00 2 Weeks
2g USD 5,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
91374-20-8 (HCl) 91374-21-9 (free base)
Synonym
Ropinirole Hydrochloride; Ropinirole HCl; SKF 101468; SKF-101,468; SKF 101468; AS-041164; AS 041164; AS041164;
IUPAC/Chemical Name
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride
InChi Key
XDXHAEQXIBQUEZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H
SMILES Code
CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl
Appearance
Light yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# CAS#91374-20-8 (Ropinirole HCl) CAS#91374-21-9 (Ropinirole free base).
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ropinirole HCl has a Ki of 29 nM for D2 receptor. Ropinirole HCl has pEC50s of 7.4, 8.4 and 6.8 for hD2, hD3 and hD4 receptors, respectively. Ropinirole HCl has no affinity for the D1 receptors.
In vitro activity:
This study showed that ropinirole can prevent rotenone-induced apoptosis in dopaminergic cell line SH-SY5Y through the D3 receptor. Ropinirole can block the rotenone-induced phosphorylation of JNK, P38 and p-c-Jun but promote the phosphorylation of ERK1/2. Ropinirole can reduce the rotenone-induced cleavages of caspase 9, caspase 3 and PARP and elevate the expression of anti-apoptotic proteins of p-Akt and bcl-2. Reference: FEBS Lett. 2008 Mar 5;582(5):603-10. https://pubmed.ncbi.nlm.nih.gov/18242171/
In vivo activity:
This study assessed the effect of serotonergic and dopaminergic system modulators (vortioxetine and ropinirole, respectively) on the pain threshold, depressive-like behavior, anxiety, and motor functions of mice with fibromyalgia-like symptoms. Intraperitoneal administration of vortioxetine and ropinirole alleviated tactile allodynia. Ropinirole showed antidepressant-like properties. In this fibromyalgia mouse model, vortioxetine and ropinirole markedly reduced pain. Reference: Molecules. 2021 Apr 20;26(8):2398. https://pubmed.ncbi.nlm.nih.gov/33924258/
Solvent mg/mL mM
Solubility
Water 100.0 336.88
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 296.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett. 2008 Mar 5;582(5):603-10. doi: 10.1016/j.febslet.2008.01.028. Epub 2008 Jan 31. PMID: 18242171. 2. Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem. 2003 Nov;87(3):631-41. doi: 10.1046/j.1471-4159.2003.02038.x. PMID: 14535946. 3. Sałat K, Furgała-Wojas A. Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice. Molecules. 2021 Apr 20;26(8):2398. doi: 10.3390/molecules26082398. PMID: 33924258; PMCID: PMC8074757. 4. Wang Y, Bouabid S, Darvas M, Zhou FM. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons. Exp Neurol. 2020 Nov;333:113427. doi: 10.1016/j.expneurol.2020.113427. Epub 2020 Jul 29. PMID: 32735872.
In vitro protocol:
1. Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett. 2008 Mar 5;582(5):603-10. doi: 10.1016/j.febslet.2008.01.028. Epub 2008 Jan 31. PMID: 18242171. 2. Maggio R, Scarselli M, Novi F, Millan MJ, Corsini GU. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem. 2003 Nov;87(3):631-41. doi: 10.1046/j.1471-4159.2003.02038.x. PMID: 14535946.
In vivo protocol:
1. Sałat K, Furgała-Wojas A. Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice. Molecules. 2021 Apr 20;26(8):2398. doi: 10.3390/molecules26082398. PMID: 33924258; PMCID: PMC8074757. 2. Wang Y, Bouabid S, Darvas M, Zhou FM. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons. Exp Neurol. 2020 Nov;333:113427. doi: 10.1016/j.expneurol.2020.113427. Epub 2020 Jul 29. PMID: 32735872.
1: Mochizuki H, Hattori N, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Long-term study of ropinirole patch in Parkinson's disease patients with/without basal l-dopa. Parkinsonism Relat Disord. 2021 Feb;83:105-109. doi: 10.1016/j.parkreldis.2020.12.023. Epub 2021 Jan 11. PMID: 33497892. 2: Nehal N, Nabi B, Rehman S, Pathak A, Iqubal A, Khan SA, Yar MS, Parvez S, Baboota S, Ali J. Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson's disease: Formulation perspective and In vitro and In vivo assessment. Int J Biol Macromol. 2021 Jan 15;167:605-619. doi: 10.1016/j.ijbiomac.2020.11.207. Epub 2020 Dec 2. PMID: 33278450. 3: Di Prima G, Campisi G, De Caro V. Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness. J Pers Med. 2020 Nov 25;10(4):242. doi: 10.3390/jpm10040242. PMID: 33255761; PMCID: PMC7711624. 4: Russell B, Barrus MM, Tremblay M, Ma L, Hrelja K, Wong C, Hynes TJ, Hobson S, Grottick AJ, Winstanley CA. GPR52 agonists attenuate ropinirole-induced preference for uncertain outcomes. Behav Neurosci. 2020 Oct 29. doi: 10.1037/bne0000391. Epub ahead of print. PMID: 33119328. 5: Rawji V, Rocchi L, Foltynie T, Rothwell JC, Jahanshahi M. Ropinirole, a dopamine agonist with high D3 affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. Neuropharmacology. 2020 Nov 15;179:108278. doi: 10.1016/j.neuropharm.2020.108278. Epub 2020 Aug 19. PMID: 32827517; PMCID: PMC7575901. 6: Chatzitaki AT, Jesus S, Karavasili C, Andreadis D, Fatouros DG, Borges O. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. Int J Pharm. 2020 Nov 15;589:119776. doi: 10.1016/j.ijpharm.2020.119776. Epub 2020 Aug 17. PMID: 32818538. 7: Rymbai E, Sugumar D, Saravanan J, Divakar S. Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of breast cancer. Med Hypotheses. 2020 Nov;144:110156. doi: 10.1016/j.mehy.2020.110156. Epub 2020 Aug 2. PMID: 32763725. 8: Wang Y, Bouabid S, Darvas M, Zhou FM. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons. Exp Neurol. 2020 Nov;333:113427. doi: 10.1016/j.expneurol.2020.113427. Epub 2020 Jul 29. PMID: 32735872. 9: Naz F, Rahul, Fatima M, Naseem S, Khan W, Mondal AC, Siddique YH. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. Neuropharmacology. 2020 Oct 15;177:108216. doi: 10.1016/j.neuropharm.2020.108216. Epub 2020 Jul 21. PMID: 32707222. 10: Kuang Z, Huang T, Li D, Zhao D, Jin J, Lin J, Zhu W, Chen W, Li M, Shen W. Structure Elucidation and Mechanistic Study of a New Dimeric Degradant in Ropinirole Hydrochloride Extended-Release Tablets. Pharm Res. 2020 Jul 8;37(7):136. doi: 10.1007/s11095-020-02863-3. PMID: 32642838. 11: Rewane A, Nagalli S. Ropinirole. 2020 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32119419. 12: Tome T, Obreza A, Časar Z. Developing an Improved UHPLC Method for Efficient Determination of European Pharmacopeia Process-Related Impurities in Ropinirole Hydrochloride Using Analytical Quality by Design Principles. Molecules. 2020 Jun 10;25(11):2691. doi: 10.3390/molecules25112691. PMID: 32531959; PMCID: PMC7321168. 13: Dudhipala N, Gorre T. Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson's Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation. Pharmaceutics. 2020 May 13;12(5):448. doi: 10.3390/pharmaceutics12050448. PMID: 32414195; PMCID: PMC7284436. 14: Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease. Mov Disord. 2020 Sep;35(9):1565-1573. doi: 10.1002/mds.28071. Epub 2020 May 12. PMID: 32396257. 15: Gungabissoon U, Kirichek O, El Baou C, Galwey N. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. Pharmacoepidemiol Drug Saf. 2020 May;29(5):591-598. doi: 10.1002/pds.4986. Epub 2020 Mar 9. PMID: 32153056; PMCID: PMC7317950. 16: Neo S, Xu Z. Prolonged penile erection in the absence of sexual stimulation following ropinirole use for restless legs syndrome. Sleep Med. 2020 Apr;68:20. doi: 10.1016/j.sleep.2019.07.029. Epub 2019 Sep 14. PMID: 32018186. 17: Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. Trends Pharmacol Sci. 2020 Feb;41(2):99-109. doi: 10.1016/j.tips.2019.12.002. Epub 2020 Jan 8. PMID: 31926602. 18: Andrabi SS, Tabassum H, Parveen S, Parvez S. Ropinirole induces neuroprotection following reperfusion-promoted mitochondrial dysfunction after focal cerebral ischemia in Wistar rats. Neurotoxicology. 2020 Mar;77:94-104. doi: 10.1016/j.neuro.2019.12.004. Epub 2019 Dec 6. PMID: 31816341. 19: Takahashi S, Morimoto S, Fukushima K, Nakahara J, Okano H. [Ropinirole Hydrochloride for ALS]. Brain Nerve. 2019 Nov;71(11):1279-1288. Japanese. doi: 10.11477/mf.1416201438. PMID: 31722314. 20: Takahashi S, Morimoto S, Okano H. [Ropinirole Hydrochloride, a Candidate Drug for ALS Treatment]. Brain Nerve. 2019 Sep;71(9):943-952. Japanese. doi: 10.11477/mf.1416201386. PMID: 31506396.

View History

CW 008

CW 008

GSK2578999A

GSK2578999A

Azalanstat mesylate

Azalanstat mesylate

Azanator maleate

Azanator maleate

Orconazole

Orconazole